Limited social interaction and difficulties in accessing needed medications and physical therapy were consequences of the COVID-19 pandemic, parents and…
Articles by Andrea Lobo
Nonadherence of spinal muscular atrophy (SMA) patients to their prescribed regimen of Evrysdi (risdiplam) — an oral solution…
Blood levels of creatinine, a byproduct of normal muscle function, may be a potential biomarker of disease severity and treatment…
Evrysdi (risdiplam) effectively improved motor function in adults with spinal muscular atrophy (SMA) type 2 or type 3,…
Young children with severe spinal muscular atrophy (SMA) have substantial loss of motor neurons in the thoracic region of…
The muscle fibers of children with spinal muscular atrophy (SMA) type 1 are substantially different from those of age-matched…
NIDO-361, Nido Biosciences’ experimental oral treatment for spinal and bulbar muscular atrophy (SBMA) — a disease type marked…
The Ministry of Health, Labour, and Welfare (MHLW) in Japan has extended the approval of Evrysdi (risdiplam) for infants…
Substantial differences in newborn screening (NBS) practices for spinal muscular atrophy (SMA) across the U.S. could impact referral patterns…
Patients with spinal muscular atrophy (SMA) in China and their caregivers have low levels of health information literacy, or…